Literature DB >> 17431372

Complications of radical cystectomy.

M Buscarini1, E Pasin, J P Stein.   

Abstract

Radical cystectomy has become a standard and arguably the best definitive form of therapy for high-grade, invasive bladder cancer. Lower urinary tract reconstruction, particularly orthotopic diversion, has been a major component in enhancing the quality of life of patients requiring cystectomy. As with any major surgery, however, complications do arise. It is important for all surgeons to be familiar with the presentation, prevention and treatment of the major causes of morbidity and mortality associated with radical cystectomy and lower urinary tract reconstruction. The complications discussed are among the most common of the complications seen with cystectomy and urinary-intestinal diversion. There are, in fact, many others that may be encountered, as the published literature testifies, and a thorough understanding as to their presentation, prevention and treatment is equally essential for a successful patient outcome. Adherence to proper surgical technique, familiarization with recent data regarding the most successful treatment methods, and attention to detail in the perioperative period are crucial for minimizing complications in any surgical undertaking. Radical cystectomy with orthotopic neobladder as well as total pelvic exenteration and its modifications need to be considered among the treatment options for patients with muscle invasive bladder cancer or advanced pelvic malignancies. Recent advances in patient selection, surgical technique, and perioperative care have led to decreased morbidity. Despite this, these procedure remain complex with the potential for both short and long-term complications. There is abundant evidence that radical cystectomy for bladder malignancies and pelvic exenteration for primary rectal cancer and cervical cancer can lead to meaningful long-term survival; however, the prognosis after pelvic exenteration for recurrent rectal cancer is not as good. The recent introduction of combined chemoradiotherapy is likely to improve local recurrence rates and may translate into more durable long-term survival. Pelvic exenteration continues to have an important role in the multimodality approach to patients with advanced pelvic malignancies. In conclusion, pelvic exenteration appears to be a safe and effective option for an experienced multi specialty surgical team in the treatment of complex locally advanced pelvic malignancy. The success of pelvic exenteration is highly dependent on good patient selection where an en bloc resection may result in prolonged disease-free survival and long term cure. In recent times the morbidity and mortality of this operation has decreased so that palliative exenteration has a role to help improve quality of life for this difficult group of patients.

Entities:  

Mesh:

Year:  2007        PMID: 17431372

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  5 in total

1.  A case of advanced rectal cancer with rectovesical and ileal fistulae that developed hyperammonemic encephalopathy.

Authors:  Masahiro Maruyama; Yoshiaki Miyasaka; Atsushi Takano; Masayuki Inoue; Kazushige Furuya; Hidemitsu Sugai; Masao Hada; Hiroshi Nakagomi
Journal:  Surg Case Rep       Date:  2015-09-24

Review 2.  The Significance of Biomechanics and Scaffold Structure for Bladder Tissue Engineering.

Authors:  Marta Hanczar; Mehran Moazen; Richard Day
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

3.  The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer.

Authors:  Andres F Correa; Katherine Theisen; Matthew Ferroni; Jodi K Maranchie; Ronald Hrebinko; Benjamin J Davies; Jeffrey R Gingrich
Journal:  Adv Urol       Date:  2015-10-13

Review 4.  Concise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go?

Authors:  Jan Adamowicz; Marta Pokrywczynska; Shane Vontelin Van Breda; Tomasz Kloskowski; Tomasz Drewa
Journal:  Stem Cells Transl Med       Date:  2017-10-10       Impact factor: 6.940

5.  Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis.

Authors:  Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Giuseppe Lucarelli; Daniela Terracciano; Daniela Pacella; Tommaso Muto; Angelo Porreca; Gian Maria Busetto; Francesco Del Giudice; Francesco Soria; Paolo Gontero; Francesco Cantiello; Rocco Damiano; Fabio Crocerossa; Abdal Rahman Abu Farhan; Riccardo Autorino; Mihai Dorin Vartolomei; Matteo Muto; Michele Marchioni; Andrea Mari; Luca Scafuri; Andrea Minervini; Nicola Longo; Francesco Chiancone; Sisto Perdona; Pietro De Placido; Antonio Verde; Michele Catellani; Stefano Luzzago; Francesco Alessandro Mistretta; Pasquale Ditonno; Vincenzo Francesco Caputo; Michele Battaglia; Stefania Zamboni; Alessandro Antonelli; Francesco Greco; Giorgio Ivan Russo; Rodolfo Hurle; Nicolae Crisan; Matteo Manfredi; Francesco Porpiglia; Giuseppe Di Lorenzo; Felice Crocetto; Carlo Buonerba
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.